Compass Pathways Opens U.S. Grant Program for Psychedelic Therapy Training

NEW YORK – Compass Pathways PLC ADR announced a new grant program inviting U.S.-based organizations to develop training content for healthcare providers who could deliver its investigational COMP360 psilocybin treatment if regulators approve it.

The London-based biotechnology company, which maintains offices in New York, said the grants will support the creation of structured materials focused on foundational psychedelic care plus a dedicated module on COMP360. The program builds on training already provided by established organizations that have prepared thousands of providers in psychedelic-assisted approaches. Compass plans to work directly with selected recipients to refine the content as it readies sites of care for a possible commercial launch of the therapy for treatment-resistant depression (TRD).

Applications opened April 14 and will be accepted through May 14. The company expects to award grants to as many as three organizations. Industry reports indicate each grant could total $250,000. The review will unfold in two stages over roughly three months, with notifications on advancement to the second stage by late May and final decisions by early July. Applicants must show experience in psychedelic training design and delivery, the ability to operate at scale, attention to access and inclusion, and alignment with regulatory expectations.

Dr. Steve Levine, Compass Pathways’ Chief Patient Officer, stated: “As we prepare for the potential commercial launch of COMP360 for treatment-resistant depression, our priority is ensuring that healthcare providers are trained, confident, and ready to deliver COMP360 treatment responsibly where eligible patients may receive care. Through this grant program, we look forward to collaborating with credible and experienced training organizations to develop high quality content to ensure multidisciplinary teams of providers are ready to deliver psilocybin treatment at scale, if approved.”

COMP360, Compass Pathways’ synthetic psilocybin formulation, holds Breakthrough Therapy designation from the FDA for TRD and has advanced through late-stage clinical testing. The company has described the therapy as a potential first-in-class option for patients who have not responded to existing treatments.